WBR0642: Difference between revisions
Jump to navigation
Jump to search
Sergekorjian (talk | contribs) No edit summary |
Sergekorjian (talk | contribs) No edit summary |
||
| Line 22: | Line 22: | ||
|SubCategory=Infectious Disease | |SubCategory=Infectious Disease | ||
|Prompt=A pharmaceutical company is manufacturing a novel antibiotic to overcome increasing resistance to macrolides. Its rationale is to create an agent that would be co-administered with azithromycin to counteract the mechanism by which bacteria become resistant to this antibiotic. Which of the following agents would be appropriate to investigate for this purpose? | |Prompt=A pharmaceutical company is manufacturing a novel antibiotic to overcome increasing resistance to macrolides. Its rationale is to create an agent that would be co-administered with azithromycin to counteract the mechanism by which bacteria become resistant to this antibiotic. Which of the following agents would be appropriate to investigate for this purpose? | ||
|Explanation=[[Image:Resistance_mechanisms.png | | |Explanation=[[Image:Resistance_mechanisms.png | 700px]] | ||
Macrolides are a class of antibiotic agents that act by inhibiting protein synthesis specifically inhibiting translocation. They bind to the 23S rRNA binding site of the 50S subunit. They are commonly used to treat atypical pneumonias, | Macrolides are a class of antibiotic agents that act by inhibiting protein synthesis, specifically by inhibiting translocation. They bind to the 23S rRNA binding site of the 50S subunit. They are commonly used to treat atypical pneumonias, chlamydia, and non-tuberculous mycobacteria among others. The mechanism of resistance to macrolides is by the methylation of the 23S rRNA binding site. A suggested mechanism to inhibit resistance it to administer an agent to inhibit bacterial methylation enzymes. | ||
|AnswerA=RNA methylation inhibitors | |AnswerA=RNA methylation inhibitors | ||
|AnswerAExp=Inhibition of RNA methylation can | |AnswerAExp=Inhibition of RNA methylation can in theory help decrease resistance to macrolides since it targets the main resistance mechanism. | ||
|AnswerB=Drug acetylation inhibitors | |AnswerB=Drug acetylation inhibitors | ||
|AnswerBExp= | |AnswerBExp=Acetylation inhibitors would work more for aminoglycoside resistance but not for macrolides | ||
|AnswerC=Beta-lactamase inhibitors | |AnswerC=Beta-lactamase inhibitors | ||
|AnswerCExp=Beta-lactamase inhibitors like tazobactam, clavulanic acid, and sulbactam are used with penicillin antibiotics to inhibit destruction of the beta-lactam ring by beta-lactamase producing bacteria. | |AnswerCExp=Beta-lactamase inhibitors like tazobactam, clavulanic acid, and sulbactam are used with penicillin antibiotics to inhibit destruction of the beta-lactam ring by beta-lactamase producing bacteria. | ||
| Line 37: | Line 37: | ||
|AnswerEExp=Drug adenylation is also a form of enzymatic modification seen in resistance to aminoglycosides not in macrolides. | |AnswerEExp=Drug adenylation is also a form of enzymatic modification seen in resistance to aminoglycosides not in macrolides. | ||
|EducationalObjectives=Resistance to macrolides is by methylation of the bacterial 23S rRNA binding site. | |EducationalObjectives=Resistance to macrolides is by methylation of the bacterial 23S rRNA binding site. | ||
|References= | |References=Walsh C. Molecular mechanisms that confer antibacterial drug resistance. Nature. 2000;406(6797):775-81. | ||
Walsh C. Molecular mechanisms that confer antibacterial drug resistance. Nature. 2000;406(6797):775-81. | |||
|RightAnswer=A | |RightAnswer=A | ||
|WBRKeyword=Antibiotic resistance, Macrolides | |WBRKeyword=Antibiotic resistance, Macrolides, | ||
|Approved= | |Approved=No | ||
}} | }} | ||
Revision as of 20:17, 12 September 2014
| Author | [[PageAuthor::Serge Korjian M.D. (Reviewed by Serge Korjian)]] |
|---|---|
| Exam Type | ExamType::USMLE Step 1 |
| Main Category | MainCategory::Microbiology, MainCategory::Pharmacology |
| Sub Category | SubCategory::Infectious Disease |
| Prompt | [[Prompt::A pharmaceutical company is manufacturing a novel antibiotic to overcome increasing resistance to macrolides. Its rationale is to create an agent that would be co-administered with azithromycin to counteract the mechanism by which bacteria become resistant to this antibiotic. Which of the following agents would be appropriate to investigate for this purpose?]] |
| Answer A | AnswerA::RNA methylation inhibitors |
| Answer A Explanation | AnswerAExp::Inhibition of RNA methylation can in theory help decrease resistance to macrolides since it targets the main resistance mechanism. |
| Answer B | AnswerB::Drug acetylation inhibitors |
| Answer B Explanation | AnswerBExp::Acetylation inhibitors would work more for aminoglycoside resistance but not for macrolides |
| Answer C | AnswerC::Beta-lactamase inhibitors |
| Answer C Explanation | AnswerCExp::Beta-lactamase inhibitors like tazobactam, clavulanic acid, and sulbactam are used with penicillin antibiotics to inhibit destruction of the beta-lactam ring by beta-lactamase producing bacteria. |
| Answer D | AnswerD::Drug efflux pump blockers |
| Answer D Explanation | AnswerDExp::Although drug efflux can be seen as a mechanism of resistance to macrolides, it is minor compared to rRNA methylation. |
| Answer E | AnswerE::Drug adenylation inhibitors |
| Answer E Explanation | AnswerEExp::Drug adenylation is also a form of enzymatic modification seen in resistance to aminoglycosides not in macrolides. |
| Right Answer | RightAnswer::A |
| Explanation | [[Explanation::
|
| Approved | Approved::No |
| Keyword | WBRKeyword::Antibiotic resistance, WBRKeyword::Macrolides |
| Linked Question | Linked:: |
| Order in Linked Questions | LinkedOrder:: |